Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)
| 118.82 Delayed Data As of Jan 17 |  -0.52 / -0.44%Today’s Change | 65.81 Today|||52-Week Range 125.72 | +3.17% Year-to-Date |
Latest ALNY News | Press Releases
| Why Alnylam Pharmaceuticals Rose 57.9% in 2019 Jan 09 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 119.34 |
| Today’s open | 119.01 |
| Day’s range | 116.16 - 119.46 |
| Volume | 860,384 |
| Average volume (3 months) | 701,765 |
| Market cap | $13.3B |
Data as of 4:00pm ET, 01/17/2020
Growth & Valuation
| Earnings growth (last year) | -39.67% |
| Earnings growth (this year) | -4.42% |
| Earnings growth (next 5 years) | +23.64% |
| Revenue growth (last year) | -16.69% |
| P/E ratio | NM |
| Price/Sales | 97.91 |
| Price/Book | 9.24 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| GLPGGalapagos NV | +1.54 | +0.68% |
| MYLMylan NV | -0.31 | -1.41% |
| BHCValeant Pharmaceutic... | +0.50 | +1.68% |
| SRPTSarepta Therapeutics... | -2.40 | -1.84% |
Data as of 6:30pm ET, 01/17/2020
Financials
| Next reporting date | February 6, 2020 |
| EPS forecast (this quarter) | -$2.22 |
| Annual revenue (last year) | $74.9M |
| Annual profit (last year) | -$761.5M |
| Net profit margin | -1,016.58% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
